New Delhi [India], April 22: The Subject Expert Committee (SEC) of the Drug Controller General of India (DCGI) has asked Bharat Biotech for additional data on its COVID-19 vaccine, Covaxin, for administering it to children aged between 2-12 years, sources said.

This development comes after the Subject Expert Committee discussed recommendations for the restricted emergency of Covaxin in children aged between 2-12 years. No recommendations have been made as of now, sources told ANI. Omicron Sub-Variant BA.2.12 of COVID-19 Found in Majority of Delhi Samples, Could Be Behind Surge: Sources.

However, the SEC, after a meeting on Thursday, has recommended restricted emergency use of Biological E's COVID-19 vaccine, Corbevax, in children aged 5-12 years, said sources. Now DCGI will be giving approval for its emergency use authorisation.

The Corbevax vaccine is currently being administered to children in the age group of 12-14 years.

The vaccination drive for children in the age group of 15-18 years commenced on January 3 this year. They are being administered Covaxin.

The drive later expanded on March 16 to include children aged between 12-14 years. They are being administered Corbevax.

Overall, India is currently administering two COVID-19 vaccines to children above 12 years.

(The above story is verified and authored by ANI staff, ANI is South Asia's leading multimedia news agency with over 100 bureaus in India, South Asia and across the globe. ANI brings the latest news on Politics and Current Affairs in India & around the World, Sports, Health, Fitness, Entertainment, & News. The views appearing in the above post do not reflect the opinions of LatestLY)